Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V591
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
V591 (also known as TMV-083) is a discontinued COVID-19 vaccine candidate that was developed by Merck following its acquisition of Themis Bioscience in 2020. The vaccine utilizes a live-attenuated measles virus vector platform, originally developed at the Institut Pasteur, to express the SARS-CoV-2 spike protein. The program was part of a broader effort by Merck to develop a single-dose vaccine that could be manufactured at scale. However, in January 2021, Merck announced the termination of the V591 clinical program after Phase 1 trial results showed that the immune responses were inferior to those observed in individuals who had recovered from natural COVID-19 infection or those who received other authorized vaccines.
- Other names
- SARS-CoV-2 vaccine (Themis Bioscience)measles-vector COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on V591.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V591.